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Abstract
Biomedical imaging techniques such as skeletal survey and 18F-fluorodeoxyglucose (FDG)/Positron Emission Tomography
(PET) are frequently used to diagnose and stage multiple myeloma (MM) patients. However, skeletal survey has limited
sensitivity as it can detect osteolytic lesions only after 30–50% cortical bone destruction, and FDG is a marker of cell
metabolism that has limited sensitivity for intramedullary lesions in MM. Targeted, and non-invasive novel probes are
needed to sensitively and selectively image the unique molecular signatures and cellular processes associated with MM.
Very late antigen-4 (VLA-4; also called a4b1 integrin) is over-expressed on MM cells, and is one of the key mediators of
myeloma cell adhesion to the bone marrow (BM) that promotes MM cell trafficking and drug resistance. Here we describe a
proof-of-principle, novel molecular imaging strategy for MM tumors using a VLA-4 targeted PET radiopharmaceutical, 64Cu-
CB-TE1A1P-LLP2A. Cell uptake studies in a VLA-4-positive murine MM cell line, 5TGM1, demonstrated receptor specific
uptake (P,0.0001, block vs. non-block). Tissue biodistribution at 2 h of 64Cu-CB-TE1A1P-LLP2A in 5TGM1 tumor bearing
syngeneic KaLwRij mice demonstrated high radiotracer uptake in the tumor (1264.5%ID/g), and in the VLA-4 rich organs,
spleen (8.861.0%ID/g) and marrow (11.662.0%ID/g). Small animal PET/CT imaging with 64Cu-CB-TE1A1P-LLP2A
demonstrated high uptake in the 5TGM1 tumors (SUV 6.661.1). There was a 3-fold reduction in the in vivo tumor uptake
in the presence of blocking agent (2.360.4). Additionally, 64Cu-CB-TE1A1P-LLP2A demonstrated high binding to the human
MM cell line RPMI-8226 that was significantly reduced in the presence of the cold targeting agent. These results provide pre-
clinical evidence that VLA-4-targeted imaging using 64Cu-CB-TE1A1P-LLP2A is a novel approach to imaging MM tumors.
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Introduction
Multiple myeloma (MM) is the second most commonly
diagnosed hematologic cancer characterized by immunoglobulin
secreting malignant plasma B-cells [1]. Over the past decade
significant advances in our understanding of the biology of MM
has led to the development of better therapeutic options and
improved disease management [2]. Myeloma arises from post-
germinal center B-cells and its pathogenesis involves both acquired
intrinsic genetic abnormalities as well as changes to the bone
marrow (BM) microenvironment [1,3]. Interactions between
myeloma cells and BM stroma enhance tumor survival [4].
Clinical and pre-clinical data have demonstrated that changes in
the expression of adhesion molecules facilitate the dissemination of
plasma cells out of the BM, leading to malignant transformation,
tumor spreading and immortalization [5]. MM cells thrive on
strong cell-receptor mediated interactions with the BM microen-
vironment [3]_ENREF_10. Consequently, therapeutics targeting
tumor-microenvironment interactions are currently being evalu-
ated clinically and pre-clinically [6,7].
Very late antigen-4 (VLA-4; also called a4b1 integrin) is one of
the critical mediators of myeloma cell adhesion to the BM stroma
(Figure 1A) [8–15]. VLA-4 is a non-covalent, heterodimeric,
transmembrane receptor that recognizes the QIDS (Gln-Ile-Asp-
Ser) and ILDV (Ile-leu-Asp-Val) motifs of two widely known
ligands, the vascular cell adhesion molecule-1 (VCAM-1) and
fibronection, respectively. It has been demonstrated that in human
MM samples, highest detection of plasma cell adhesion molecules
was found in patients with active MM [16].
VLA-4 has also been implicated in promoting the activity of
bone-resorbing osteoclasts in MM by up-regulating secretion of
osteoclast activating factors such as macrophage inflammatory
protein (MIP)-1a and MIP-1b [10]. These findings suggest that
VLA-4 is a MM marker that is associated with myeloma cell
trafficking. Michigami et al. used the a4b1 (VLA-4) positive murine
myeloma cell line 5TGM1 and mouse marrow stromal cell line
ST2, which expresses VCAM-1, to show that the interaction of
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myeloma cells with stromal cells via a4b1-integrin/VCAM-1
produces osteoclastogenic activity, suggesting that the presence
of stromal cells provide a microenvironment for exclusive
colonization of myeloma cells in the BM [12].
VLA-4 also plays an important role in the development of
chemotherapy resistance. Noborio-Hatano et al. reported that high
expression of VLA-4 on the cell surface leads to acquisition of
chemotherapy resistance in MM [8]. VLA-4 mediated adhesion
and an up-regulated VLA-4 axis is also observed in MM patients
who demonstrate chemotherapeutic resistance [17–19]. VLA-4,
therefore, is a useful marker of tumor cell trafficking, osteoclast
stimulation and drug resistance in MM.
Biomedical imaging techniques such as FDG/PET, skeletal
survey, bone scintigraphy and MRI are routinely used for
staging and post-treatment follow up in MM patients [20].
More importantly, imaging of the skeleton with the aim of
detecting lytic bone lesions is needed to discriminate MM from
its precursor states such as smoldering MM (sMM) and
monoclonal gammopathy of undetermined significance (MGUS)
[21]. Radiographic skeletal survey can detect osteolytic lesions
only after 30%–50% cortical bone destruction, limiting its
sensitivity for imaging early stage myeloma bone lesions. MRI
and FDG-PET/CT are comparatively better at detecting bone
marrow plasma cell infiltration than conventional radiographs
[22]. However, MRI has limitations such as prolonged
acquisition time (45–60 min), limiting patient factors such as
claustrophobia or metal devices in the body, and particularly,
the limited field of view of MRI is not reliable for investigating
bones such as skull, clavicle or ribs, and causes frequent under-
staging. FDG is a marker of cell metabolism that has limited
sensitivity (61%) for intramedullary lesions in MM [23].
Additionally, FDG/PET scan is not recommended within two
months following therapy due to high likelihood of healing
related (flare phenomenon) false positives. Currently, there are
no specific MM imaging agents used clinically. VLA-4 targeted
novel molecular imaging of MM has the potential to improve
early-stage diagnosis and the management of patients receiving
compounds that affect the tumor cells as well as the
microenvironment.
Here, we evaluated a VLA-4 targeted PET radiopharmaceu-
tical, 64Cu-CB-TE1A1P-LLP2A, (Figure 1B) for PET imaging of
VLA-4 positive murine myeloma 5TGM1 MM tumors. For the
proof-of-principle imaging studies, we used the 5TGM1 mouse
model of bone marrow disseminated mouse MM. The 5TGM1-
into-KaLwRij model originates from spontaneously developed
MM in aged C57BL/KalwRij mice and has since been
propagated by intravenous injection of BM cells from MM
bearing mice, into young naive syngeneic recipients [24]. Cell
Figure 1. Schematic diagram depicting the interaction of multiple myeloma (MM) and stromal cells. A. Very late antigen-4 (VLA-4, also
known as integrin a4b1) is over expressed on MM cells. VLA-4 mediates myeloma cell adhesion to the bone marrow (BM) stroma through interactions
with fibronectin, a glycoprotein of extracellular matrix (ECM) protein and vascular cell adhesion molecule-1 (VCAM-1) protein expressed on bone
marrow (BM) stromal cells. B. Structure of CB-TE1A1P-LLP2A.
doi:10.1371/journal.pone.0055841.g001
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uptake and binding assays performed with 5TGM1 cells demon-
strated receptor specific binding of the imaging probe. Tissue
biodistribution and small animal PET/CT imaging studies
demonstrated highly sensitive and specific uptake of the imaging
probe by the subcutaneous (s.c.) and intra-peritoneal (i.p.) 5TGM1
tumors, and suspected tumor cells and associated inflammatory
cells in the BM. Additionally, the imaging probe demonstrated
high binding to the human MM cells RPMI-8226 in vitro that was
significantly blocked (P,0.0001) in the presence of the cold
targeting ligand. Pilot imaging studies in the orthotopic (intrave-
nous, i.v.) mouse models of mouse (5TGM1) and human (RPMI-
8226) MM are ongoing.
Materials and Methods
Ethics Statement
All experiments involving the use of radioactive materials at
Washington University were conducted under the authorization of
the Radiation Safety Committee in accordance with the Uni-
versity’s Nuclear Regulatory Commission license. All animal
studies were performed under the Guide for the Care and Use of
Laboratory Animals under the auspices of the Washington
University Animal Studies Committee. This study was approved
by the Washington University Animal Studies Committee (Animal
protocol # 20090058).
Materials
Copper-64 (t1/2 = 12.7 h, b
+; 17.8%, Eb+ max = 656 KeV, b
-,
38.4%, Eb -max = 573 KeV) was produced on a CS-15 biomedical
cyclotron at Washington University School of Medicine [25]. All
chemicals were purchased from Sigma-Aldrich (St. Louis, MO),
unless otherwise specified, and solutions were prepared using
ultrapure water (18 MV-cm resistivity). Radiochemistry reaction
progress and purity were monitored by analytical reversed-phase
high performance liquid chromatography (HPLC), which was
performed on a Waters 600E chromatography system (Milford,
MA) with a Waters 991 photodiode array detector and an Ortec
Model 661 radioactivity detector (EG&G Instruments, Oak Ridge,
TN). An Altima C18 RocketH column was employed with a
gradient that changes from 0.1% TFA in water to 30:70
0.1%TFA/Water:0.1%TFA/CH3CN over the course of 5 min.
Radioactive samples were counted using a Beckman 8000
(Franklin Lakes, NJ) automated well-type gamma-counter. PET
and CT data were acquired using an Inveon Pre-clinical Imaging
Station.
Synthesis and 64Cu Radiolabeling of CB-TE1A1P-LLP2A
CB-TE1A1P was prepared as previously described [26]. Briefly,
CB-TE1A1P-LLP2A was designed to have CB-TE1A1P attached
to the side chain of Lys and 2 hydrophilic linkers between LLP2A
and Lys(CB-TE1A1P). The detailed synthesis of CB-TE1A1P-
LLP2A was previously reported [27]. For radiolabeling, Cu-64
chloride (64CuCl2) (5210 mL in 0.5 M HCl) was diluted with 0.1
M ammonium acetate buffer (pH 8, 502100 mL). The CB-
TE1A1P-LLP2A solution (5 mg) was diluted with acetate buffer,
64Cu-acetate (185 MBq (5 mCi)) was added, and the mixture was
incubated at 80–95uC for 5 min or at room temperature for 45–60
minutes. After purification, the radiochemical purity (RCP) of the
64Cu-labeled CB-TE1A1P-LLP2A was monitored by radio-
HPLC.
Cell Lines
The human myeloma cell line RPMI-8226 was obtained from
the American Type Culture Collection (ATCC). The previously
published mouse MM cell line 5TGM1 [28] (a gift from Dr. G.
Mundy, Vanderbilt University, Nashville, Tennessee) was grown
in DMEM supplemented with 10% fetal bovine serum, penicillin
(100 U/ml) and streptomycin (50 mg/ml). Long term culture of
the cells occurred in a water jacketed incubator at 37uC and 5%
CO2. Assays were also carried out under these respective
conditions.
Flow Cytometry
PE-conjugated mAb to mouse CD49d (Integrin alpha 4) was
purchased from eBioscience. 5TGM1 cells were prepared for flow
cytometry by incubating cells with mAb followed by PBS washes.
Data collection and analyses were performed on a FACScalibur
flow cytometer (Becton Dickinson Immunocytometry Systems,
Mountain View, California, USA).
In Vitro Cell Uptake Assay
Cell uptake assays were performed in murine 5TGM1 and
human RPMI-8226 myeloma cells using 64Cu-CB-TE1A1P-
LLP2A to determine the sum of cell internalized and surface-
bound fractions. Cells were grown in Iscoves MDM until 60275%
confluent, harvested by mechanical dissociation, and re-suspended
in the binding medium (phosphate buffered saline [PBS], 0.1%
bovine serum albumin [BSA] and 1 mM Mn2+) in 1.5 mL
microfuge tubes. A solution of 64Cu-CB-TE1A1P-LLP2A
(0.1 nM) was added to the cell suspension. The samples were
incubated for 60 min in a cell incubator (37uC, 5% CO2). To
determine the in vitro VLA-4 binding specificity of 64Cu-CB-
TE1A1P-LLP2A, samples were co-incubated with ,200-fold
excess of the unlabeled ligand, LLP2A. After incubation, the
samples were centrifuged at 1,500 rpm for 5 min, and the
radioactive medium was removed. Cell pellets were rinsed with
ice cold binding buffer (500 mL) and centrifuged at 1,500 rpm for
3 min (2 X). The radioactivity in cell pellets was measured in a
well counter (Packard II gamma counter).
In Vitro Saturation Binding Assay
For saturation binding experiments, 64Cu-CB-TE1A1P-LLP2A
(0.5–15.5 nM) was incubated with ,250,000 5TGM1 (, 0.41 mg
protein) whole cells in 1.5 mL microfuge tubes for 2 h at 4uC in a
total volume of 500 mL of binding medium (phosphate buffered
saline [PBS], 0.1% bovine serum albumin [BSA] and 1 mM
Mn2+). The reaction tubes were put on a slow moving rotor during
the 4uC incubation. After the incubation, samples were centri-
fuged at 1,500 rpm for 5 min, reaction buffer was removed by
vacuum aspiration and the cells were washed two times with ice
cold PBS. Non-specific binding was determined by conducting the
assay in the presence of an excess (,200 fold) unlabeled LLP2A.
The radioactivity in the cell pellets was measured in a well counter
(Packard II gamma counter). The specific binding was obtained by
the subtraction of non-specific binding from total binding. The
dissociation constant (Kd) and receptor density (Bmax) were
estimated from the non-linear fitting of the specific binding versus
the concentration of 64Cu-CB-TE1A1P-LLP2A using Prism
software (GraphPad, San Diego, CA).
Mouse Models of MM
KaLwRij mice (from Dr. Claire M. Edwards, Vanderbilt
University Medical Center Cancer Biology, Nashville, TN) were
housed in ventilated cage racks and allowed food and water.
5TGM1 cells in log phase growth were prepared for injection by
precipitation in a centrifuge followed by a wash step with sterile
endotoxin-free PBS. Finally, the cells were re-suspended in
PET iImaging of Multiple Myeloma
PLOS ONE | www.plosone.org 3 February 2013 | Volume 8 | Issue 2 | e55841
endotoxin-free PBS at a concentration of 16106 cells/mL and
injected with or without matrigel, respectively, in the nape of the
neck subcutaneously (s.c.) or intraperitoneally (i.p.) in a 100 mL
volume in 3–5 week old mice. The tumors were allowed to grow
for an average of 10 d.
Serum Protein Electrophoresis (SPEP) Analysis
Mice were bled by tail grazing at the desired time point. Blood
was collected into Microtainer tubes (Becton Dickinson) and was
centrifuged for 10 min at 2,300 g. Sera were diluted 1:2 in normal
saline buffer and analyzed by serum protein electrophoresis (SPEP)
on a QuickGel Chamber apparatus using pre-casted QuickGels
(Helena Laboratories) according to manufacturer’s instruction.
Densitometric analysis of the SPEP traces was performed using the
clinically certified Helena QuickScan 2000 workstation, allowing a
precise quantification of the various serum fractions, including the
measurements of gamma/albumin ratio.
Histological Analysis
After sacrifice from the biodistribution and the small animal
imaging studies, the tumor sections were stained with hema-
toxylin and eosin (H&E) and visualized under a Nikon Eclipse
TE300 microscope equipped with a Plan Fluor 20/0.45
objective lens (Nikon) and a Magnafire digital charge-coupled
device camera.
Biodistribution Studies in 5TGM1 Tumor-bearing Mice
5TGM1 tumor bearing mice were sacrificed at 2 or 24 h after
the injection of the radiopharmaceutical, 64Cu-CB-TE1A1P-
LLP2A. Blood, marrow, fat, heart, stomach, intestines, lungs,
liver, spleen, kidneys, muscle, bone, pancreas, and tumor were
harvested, weighed, and counted in the c-counter. For the in vivo
blocking studies, an additional group of mice was injected with the
radiopharmaceutical premixed with,200-fold excess of LLP2A to
serve as a blocking agent and sacrificed at the respective time
point. The percent injected dose per gram of tissue (%ID/g) was
determined by decay correction of the radiopharmaceutical for
each sample normalized to a standard of known weight, which was
representative of the injected dose.
Small Animal Imaging Experiments
Prior to small animal PET/CT imaging, mice were injected
intravenously (tail vein) with 64Cu-CB-TE1A1P-LLP2A (0.9 MBq
(SA: 37 MBq/mg)). At 2 h post injection, mice were anaesthetized
with 1–2% isoflurane and imaged with small animal PET (Focus
220 or Inveon (Siemens Medical Solutions, Knoxville,TN)), while
the CT images were acquired with the Inveon. Static images were
collected for 30 min and co-registered using the Inveon Research
Workstation (IRW) software (Siemens Medical Solutions, Knox-
ville,TN). PET images were re-constructed with the maximum a
posteriori (MAP) algorithm [29]. The analysis of the small animal
PET images was done using the IRW software. Regions of interest
(ROI) were selected from PET images using CT anatomical
guidelines and the activity associated with them was measured
with IRW software. Maximum standard uptake values (SUVs) for
both experiments were calculated using SUV= ([nCi/mL]x[ani-
mal weight (g)]/[injected dose (nCi)]). A set of mice was also
imaged at 24 h post injection.
Data Analysis and Statistics
All data are presented as mean6SD. For statistical classifi-
cation, a Student’s t test (two-tailed, unpaired) was used to
compare individual datasets. All statistical analyses were
performed using Prism software. P values less than 0.05 were
considered significant.
Results
Radiochemistry and In Vitro Studies
Radiochemical purity for 64Cu-CB-TE1A1P-LLP2A was
.95% as determined by radio-high performance liquid chroma-
tography (radio-HPLC). The specific radioactivity for 64Cu-CB-
TE1A1P-LLP2A was 37 MBq/mg.
64Cu-CB-TE1A1P-LLP2A Binding to VLA-4 in 5TGM1
Murine Myeloma Cells
5TGM1 cells demonstrated high expression (.85% of cells
staining positive) of a-4 by flow cytometry when normalized to the
isotype control (Figure 2A). The cellular uptake (sum of the cell-
internalized and cell surface-bound fractions) at 37uC of 64Cu-CB-
TE1A1P-LLP2A in 5TGM1 cells in the presence and absence of
the blocking agent (non-radiolabeled ligand, LLP2A) was signif-
icantly different (p,0.0001, Figure 2B).
The in vitro binding affinity of 64Cu-CB-TE1A1P-LLP2A was
investigated by determining the equilibrium dissociation constant
(Kd) and the maximum specific binding (Bmax) of the radiolabeled
conjugate to 5TGM1 cells in saturation binding assays. A large
excess (200-fold excess) of unlabeled LLP2A was added to a
parallel set of cells to saturate receptor binding sites and account
for non-specific binding. A representative saturation binding curve
and Scatchard transformation of 64Cu-CB-TE1A1P-LLP2A to
5TGM1 cells is shown in Figure 2C. The data show that in the
concentration range of 0.5–15.5 nM, 64Cu-CB-TE1A1P-LLP2A is
bound to a single class of binding sites with a Kd of 2.2 nM (60.9)
and Bmax of 136 pmol/mg (619).
Biodistribution of 64Cu-CB-TE1A1P-LLP2A in 5TGM1
Tumor Bearing Immunocompetent/KaLwRij Mice
In vivo biodistribution of 64Cu-CB-TE1A1P-LLP2A was evalu-
ated in KaLwRij mice bearing subcutaneous 5TGM1 tumors
(Figure 3). Uptake of the radiotracer was high in the 5TGM1
tumors (12.0464.50%ID/gram). As expected, tracer uptake was
highest in the VLA-4 rich hematopoietic organs, spleen
(8.861.0%ID/gram) and marrow (11.662.1% ID/g). In a
separate cohort of tumor-bearing mice, excess of cold LLP2A
ligand was co-administered with 64Cu-CB-TE1A1P-LLP2A. In
the presence of the blocking agent, the radiotracer uptake was
significantly reduced in the tumor, spleen and bone (p,0.05),
demonstrating the in vivo binding specificity of 64Cu-CB-TE1A1P-
LLP2A (Figure 3, open bars). Biodistribution of 64Cu-CB-
TE1A1P-LLP2A in non-tumor bearing KaLwRij mice was similar
to tumor-bearing mice, with spleen and BM being the key uptake
organs (data not shown).
Small Animal Imaging Experiments
To test the ability of 64Cu-CB-TE1A1P-LLP2A to image MM,
small animal PET/CT imaging was conducted in KaLwRij mice
bearing 5TGM1 murine myeloma tumors. The following i.p. and
s.c. 5TGM1 models were used for the proof-of-principle imaging
studies: 1) a non-matrigel assisted s.c. (plasmacytoma) tumor in the
flank of the mouse (Figure 4B); 2) a matrigel assisted s.c. tumor in
the flank of the mouse (Figure 4C); and 3) tumor cells injected in
the peritoneal (i.p.) cavity (Figure 4D). Figure 4 contains four (B-D)
representative maximum intensity projection (MIP) small animal
PET images using 64Cu-CB-TE1A1P-LLP2A (0.9 MBq, 0.05 mg,
27 pmol, SA: 37 MBq/mg) at 2 h post injection in the various
PET iImaging of Multiple Myeloma
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models compared to a non-tumor-bearing control mouse
(Figure 4A). The small animal PET images with 64Cu-CB-
TE1A1P-LLP2A demonstrate that the VLA-4 targeted radiophar-
maceutical has high sensitivity for detecting myeloma tumors of
different sizes and heterogeneity, as even early stage, non-palpable,
millimeter sized tumor lesions were clearly imaged (Figure 4B).
The SUV of the tumor shown in Figure 4D was not determined
due to the large tumor size and overlap with the spleen and
bladder. The heterogeneous distribution of the imaging agent in
Figure 4D likely corresponds with the heterogeneity of the tumor
mass. The uptake of 64Cu-CB-TE1A1P-LLP2A in i.p. tumors was
determined to be 14.962.6%ID/g by post PET biodistribution
(2 h post injection). Images collected at 24 h demonstrated
significantly improved tumor to background ratios as compared
to 2 h (Figure 5). Supplemental image 1 shows a representative
small animal PET/CT MIP image of a mouse bearing s.c.
5TGM1 tumor at 2 h and 24 h respectively. The in vivo targeting
specificity was demonstrated by blocking with excess LLP2A
(,200 fold), which led to reduced uptake in the 5TGM1 MM
tumors. As shown in Figure 6, there was a 3-fold (P,0.05)
reduction in cumulative tumor SUVs in the presence of the
blocking agent (6.261.1 vs. 2.360.4). A representative MIP image
of the reduced tumor uptake is shown in Figure 6 inset. Together,
these data demonstrate that 64Cu-CB-TE1A1P-LLP2A can be
used to image murine MM tumors in a variety of anatomic sites.
All the images are scaled the same, demonstrating that although
there is uptake in the spleen of a non-tumor bearing mouse (SUV:
2.2), the uptake is higher in the spleens of tumor bearing mice
(SUV: 3.3). We are currently investigating the imaging of
myeloma induced spleen pathology (splenomegaly) in orthotopic
(i.v.) 5TGM1 mouse models of MM.
Figure 2. Flow cytometry, cell uptake and saturation binding data. A. Greater than 85% of a4 (VLA-4)-positive cells in total 5TGM1 tumor cell
population as determined by flow cytometry (Anti-Mouse CD49d (integrin a-4). B. Cell uptake of 64Cu-CB-TE1A1P-LLP2A (0.1 nM), in 5TGM1 cells at
37uC (p,0.0001). C. Saturation binding curve for 64Cu-CB-TE1A1P-LLP2A gave a Kd of 2.2 nM (61.0) and Bmax of 136 pmol/mg (619). N = 3 (Inset:
Scatchard transformation of saturation binding data).
doi:10.1371/journal.pone.0055841.g002
PET iImaging of Multiple Myeloma
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e55841
Figure 3. Tissue biodistribution of 64Cu-CB-TE1A1P-LLP2A in 5TGM1 s.c. tumor mice. Biodistribution of 64Cu-CB-TE1A1P-LLP2A in 5TGM1
s.c. tumor mice (black bars). The open bars represent biodistribution in the presence of non-radioactive blocking agent (, 200 fold excess LLP2A).
Mice were injected with 64Cu-CB-TE1A1P-LLP2A (0.01 mg, 0.2 MBq, SA: 37 MBq/mg) and sacrificed at 2 h post injection. N= 4 mice/group.
doi:10.1371/journal.pone.0055841.g003
Figure 4. Representative maximum intensity projection (MIP) small animal PET/CT images. A. non-tumor KaLwRij control mouse. B. a
small sized, non-palpable, early stage subcutaneous (s.c.) 5TGM1 murine tumor in the nape of the neck inoculated without the use of matrigel (tumor
SUV 2.24). White arrows point to suspected tumor cells and associated tumor supporting cells in the BM of the long bones and spine. C. matrigel
assisted s.c. 5TGM1 tumor in the nape of the neck (tumor SUV 6.2). D. mouse injected intraperitoneally (i.p.) with 5TGM1 murine myeloma cells. All the
mice were injected with 64Cu-CB-TE1A1P-LLP2A (0.9 MBq, 0.05 mg, 27 pmol) and were imaged by small animal PET/CT at 2 h post-injection. *All
tumor bearing animals were SPEP (Serum Protein Electrophoresis) positive. T = Tumor; S = Spleen. N = 4/group.
doi:10.1371/journal.pone.0055841.g004
PET iImaging of Multiple Myeloma
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Confirmation of 5TGM1 Tumor Burden by Histological
and Serum Protein Electrophoresis (SPEP) Analysis
A representative hematoxylin and eosin (H&E) slide of a
5TGM1 s.c. tumor tissue from those imaged in Figure 4 is shown
in Figure 7A. The tumor cells show irregularly shaped nuclei and
increased mitosis consistent with myeloma pathogenic features.
The SPEP test is used clinically to measure clonal c-globulin (M
protein) in the blood to quantify disease burden in MM. SPEP
analysis was performed on all tumor-bearing mice. Qualitative and
quantitative analyses of the SPEP gels indicated increased M-
protein (gamma protein band) in tumor bearing mice as compared
to non-tumor control mice.
Binding of 64Cu-CB-TE1A1P-LLP2A to Human RPMI-8226
Myeloma Cells
Binding of 64Cu-CB-TE1A1P-LLP2A was evaluated in human
MM cell line RPMI-8226 in vitro. RPMI-8226 cell uptake
experiments demonstrated high uptake of 64Cu-CB-TE1A1P-
LLP2A that was significantly blocked in the presence of excess
LLP2A (P,0.0001) (Figure 8).
Discussion
This study demonstrates novel imaging of MM tumors using a
high-affinity, VLA-4 (integrin a4b1) targeted PET probe, in a s.c.
and i.p. (extra-osseous) immunocompetent mouse model of MM.
Clinically, MM is characterized by the presence of end-organ
damage such as lytic bone disease, anemia, hypercalcemia, and
renal insufficiency [30]. While laboratory tests such as serum
protein electrophoresis (SPEP), urine protein electrophoresis, bone
marrow evaluation, and serum free light chains are key to making
a preliminary diagnosis, molecular imaging assists in locating the
tumor lesion within the bone and outside the bone. Imaging of the
skeleton, with the aim to rule out lytic bone lesions, is important to
discriminate MM from its precursor states. FDG-PET/CT fusion
imaging has the ability to detect diffuse or focal lesions in the bone
marrow prior to destruction of mineralized bone as well as
extramedullary disease in patients [31,32]. However, FDG-PET/
CT is often not effective at imaging subsets of myeloma patients
presenting drug resistant (DR) tumors due to intrinsically limited
metabolic rates of the DR tumors [33–35]. Moreover, FDG-PET/
CT also has limitations in the diagnosis or staging of clinically
organ-confined or locally recurrent disease since FDG uptake is
increased in cells and tissues undergoing rapid division, growth,
and inflammatory response. These processes are transient and are
not necessarily tumor-specific [36,37]. VLA-4 based molecular
imaging could effectively address these limitations by providing
tumor specific information based on receptor status.
In the current study, we evaluated a newly developed mono-
acid, mono-phosphonate chelator, CB-TE1A1P, conjugated with
a high VLA-4 affinity (IC50 = 2 pM) peptidomimetic ligand,
LLP2A for PET imaging of MM [27]. LLP2A is comprised of
D- and unnatural amino acids which makes it resistant to proteases
in human plasma, and has been evaluated as a promising VLA-4
specific therapeutic agent that possesses safety features for
potential human use [38]. The conjugate, CB-TE1A1P-LLP2A,
can be labeled with Cu-64 in high specific activity under mild
conditions [39]. The VLA-4 positive 5TGM1 murine myeloma
cells, used for the in vitro and in vivo studies were an ideal selection
for the described proof-of-principle imaging studies [28,40]. For
the animal experiments described in this study, i.p. or s.c.
injections of 5TGM1 cells in syngeneic KaLwRij mice led to
reproducible extra-osseous tumors. Small animal PET/CT with
64Cu-CB-TE1A1P-LLP2A was supported by cell binding studies,
Figure 5. Graph representing tumor to muscle and blood
respectively at early and late time-points. The Tumor/Muscle and
Tumor/Blood ratios at 2 h and 24 h respectively calculated from the
MIP images (SUVs). The ratios were higher at 24 h indicating improved
contrast after clearance of the radioactive probe from the background
tissues over time.
doi:10.1371/journal.pone.0055841.g005
Figure 6. Graph representing in vivo blocking of 64Cu-CB-
TE1A1P-LLP2A. Averaged tumor MIP SUV’s (N = 4) calculated from
small animal PET images in the presence and absence of the blocking
agent, LLP2A. Inset-Representative MIP image showing mice with
similar tumors in the nape of the neck imaged in the absence (L) and
presence (R) of the blocking agent (LLP2A). Mice were imaged with
small animal PET and 64Cu-CB-TE1A1P-LLP2A at 2 h post-injection
(0.9 MBq, 0.05 mg, 27 pmol, (SA: 37 MBq/mg). Blocking dose: ,200 fold
excess than the tracer amount. P,0.05.
doi:10.1371/journal.pone.0055841.g006
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SPEP analysis, and ex-vivo tissue biodistribution and tumor
histology.
The 5TGM1 cell binding of 64Cu-CB-TE1A1P-LLP2A was
significantly reduced in the presence of excess LLP2A at 37uC and
4uC respectively, signifying receptor mediated endocytosis. The
saturation binding assays were performed in the presence of Mn2+
ions and produced high Bmax values (136 pmol/mg (619)), which
is key to a desirable imaging outcome resulting from the high
binding potential (Bmax/Kd) ratio [41]. Cell uptake studies
performed in the absence of receptor activating cations, in this
case, Mn2+, resulted in much lower binding (data not shown). Lam
and co-workers have also shown independently that LLP2A binds
to the activated form of a4b1 integrin [38,42]. Additional studies
will be needed to describe the changes in VLA-4 activation status
in response to different stimuli [43]. Binding of 64Cu-CB-TE1A1P-
LLP2A was evaluated in the human MM cell line, RPMI-8226.
64Cu-CB-TE1A1P-LLP2A demonstrated high binding to RPMI-
8226 cells, which was significantly blocked in the presence of
excess LLP2A (Figure 8).
The ex vivo biodistribution and in vivo imaging studies in the
5TGM1 mouse models of MM support the fact that 64Cu-CB-
TE1A1P-LLP2A has desirable in vivo pharmacokinetics for
achieving excellent tumor to background ratios. Three 5TGM1
tumor models were evaluated in this study to demonstrate the
versatility of the PET imaging probe. In the mouse bearing s.c.
tumor cells without matrigel, PET imagining readily detected the
presence of VLA-4 expressing cells localized to the femur, tibia,
and spine (Figure 4B, arrows). While this signal is presumed to
indicate dissemination of myeloma cells to the bone, further ex vivo
analyses will be required to characterize the extent that
inflammatory or stromal cells may also be imaged as components
of the pre-metastatic niche. Regardless, this data demonstrates that
VLA-4-targeted PET imaging has the ability to image cells within
mineralized bone. In vivo tumor blocking of 64Cu-CB-TE1A1P-
LLP2A was observed in both the biodistribution and small animal
PET imaging studies. Small animal PET images collected at 2 h
post-injection had high tumor to muscle ratios (2866) (Figure 5
and supplemental image 1), with improved ratios observed at 24 h
time point due to the clearance from non-targetorgans (161641).
In summary, here we have described for the first time use of a
VLA-4 targeted PET imaging probe, 64Cu-CB-TE1A1P-LLP2A,
to image extra-osseous MM tumors in animal models using small
animal PET/CT and tissue biodistribution. Future work will
expand the approach to perform longitudinal imaging studies
focused on intra-medullary tumor lesions in mouse models of
mouse and human MM. Additionally, we will evaluate VLA-4
expression as a marker of effective therapy by molecular imaging,
and the results will be compared with the existing imaging
standards such as FDG-PET/CT and MRI.
Supporting Information
Figure S1 Small animal PET/CT images showing high
tumor uptake at early and late time points. Representative
maximum intensity projection (MIP) images of the same mouse
Figure 7. Tumor histology and SPEP (Serum Protein Electro-
phoresis) analysis on the serum of KaLwRij mice. A. Hematoxylin
and eosin (H&E) stained slide of a representative 5TGM1 s.c. tumor
tissue. The tumor cells show irregularly shaped nuclei and increased
mitosis consistent with myeloma pathogenic features. B. SPEP gel
showing qualitatively the c-globulin (M protein) in tumor bearing (lanes
5, 6 & 7) and non-tumor bearing (lanes 1, 2, 3 & 4) mice. The 5TGM1
tumor bearing mice (lanes 5, 6 & 7) were analyzed two weeks post
tumor cell inoculation. The top arrow represents the M Protein band
and the lanes represent serum SPEP for each mouse. C) Quantitative
representation of the total c-globulin g/dl in the mice (1–7).
doi:10.1371/journal.pone.0055841.g007
Figure 8. Cellular uptake of 64Cu-CB-TE1A1P-LLP2A in human
myeloma RPMI-8226 cells. Cell uptake of 64Cu-CB-TE1A1P-LLP2A
(0.1 nM), in human RPMI-8226 cells at 37uC in the absence (red bar) and
presence (blue bar) of excess LLP2A (P,0.0001).
doi:10.1371/journal.pone.0055841.g008
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bearing matrigel assisted s.c. 5TGM1 tumor in the nape of the
neck at 2 h and 24 h post injection. Over time, the tumor to
background ratios are improved as the radioactive probe clears out
from non-target organs.
(TIF)
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